Search alternatives:
significantly increased » significant increase (Expand Search)
increased decrease » increased release (Expand Search), increased crash (Expand Search)
linear decrease » linear increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significantly increased » significant increase (Expand Search)
increased decrease » increased release (Expand Search), increased crash (Expand Search)
linear decrease » linear increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
2281
-
2282
-
2283
-
2284
-
2285
-
2286
Increased CN inhibition leads to reduced STO frequency and to more CSpk frequency.
Published 2025“…(E) Increase in CN-to-IO inhibitory synapses, and thus inhibition strength, led to a decrease in IO STO frequency and a concurrent increase in CSpk frequency.…”
-
2287
MXene/Bi<sub>2</sub>O<sub>3</sub> Nanocomposites as Supercapacitors for Portable Electronic Devices
Published 2025“…2D MXene nanosheets often encounter challenges such as aggregation and restacking, which can significantly decrease their performance in supercapacitor applications. …”
-
2288
-
2289
-
2290
-
2291
-
2292
-
2293
-
2294
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
2295
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
2296
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
2297
-
2298
BMI distribution of study population using World Health Organisation (WHO) categories.
Published 2025Subjects: -
2299
-
2300
Patient demographics by BMI missingness in the United Kingdom NJR data and Danish data.
Published 2025Subjects: